Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-05-24
1997-03-18
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514832, 514833, A61K 3816
Patent
active
056123108
ABSTRACT:
The present invention is directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone.
REFERENCES:
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4061736 (1977-12-01), Morris et al.
patent: 4301144 (1981-11-01), Iwashita
patent: 4321259 (1982-03-01), Nicolau
patent: 4377512 (1983-03-01), Ajisaka
patent: 4412989 (1983-11-01), Iwashita
patent: 4473563 (1984-09-01), Nicolau
patent: 4584130 (1986-04-01), Bucci et al.
patent: 4598064 (1986-07-01), Walder
patent: 4650786 (1987-03-01), Wong
patent: 4670417 (1987-06-01), Iwasaki
patent: 4710488 (1987-12-01), Wong
patent: 4812449 (1989-03-01), Rideout
patent: 5028588 (1991-07-01), Hoffman et al.
patent: 5266594 (1993-11-01), Dawson et al.
patent: 5273875 (1993-12-01), Griffith
patent: 5295944 (1994-03-01), Teicher et al.
patent: 5296466 (1994-03-01), Kilbourn et l.
patent: 5298490 (1994-03-01), Heavner et al.
patent: 5298506 (1994-03-01), Stamler et al.
patent: 5312835 (1994-05-01), Kilbourn et al.
patent: 5317040 (1994-05-01), Goldman
patent: 5334380 (1994-08-01), Kilbourn et al.
Ramsay et al., Int. J. Radiation Oncology Biol. Phys. vol. 22, pp. 721-725 (1992).
W. A. Denny, 1995, Ninth International Conference on Chemical Modifier of Cancer Treatment, abstract, p. 33.
Gatenby et al., 1988, Int. J. Radiation Oncology Biol. Phys. 14:831-838.
Hockel et al., 1993, Radiotherapy Oncology 26:45-50.
R. K. Jain, 1988, Cancer Res. 48:2641-2658.
R. K. Jain, 1989, J. Natl. Cancer Inst. 81:570-576.
Kavanagh et al., 1993, Br. J. Cancer 67:734-741.
Karuri et al., 1993, Br. J. Cancer 68:1080-1087.
Less et al., 1992, Cancer Res. 52:6371-6374.
Leunig et al., 1992, cancer Res. 52:6553-6560.
Maeda et al., 1995, Jpn. J. Cancer Res. 85:331-334.
Martin et al., 1993, Radiotherapy Oncology 27:123-130.
Roh et al., 1991, Cancer Res. 51:6695-6698.
Vaupel et al., 1989, Cancer Res. 49:6449-6465.
Wood et al., 1994, Cancer Res. 54:6458-6463.
Andrade et al., "Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature," Br. J. Pharmacol. 107:1092-1095, 1992.
Babbs and DeWitt, "Physical principles of local heat therapy for cancer," Med. Instrum. 15:367-373, 1981.
Botstein and Shortle, "Strategies and applications of in vitro mutagenesis," Science 229:1193-1201, 1985.
Brown and Koong, "Therapeutic advantage of hypoxic cells in tumors: a theoretical study," J. Natl. Cancer Inst. 83:178-185, 1991.
Caruthers et al., "New methods for synthesizing deoxyoligonucleotides," Genetic Engineering, J.K. Setlow and A. Hollaender eds., Plenum Press, New York, vol. 4, pp. 1-17, 1982.
Chapman et al., "Keynote address: cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells," Int. J. Rad. Oncology, Biol. Phys. 16:911-917, 1987.
Collman et al., "`Picket fence porphyrins.`Synthetic models for oxygen binding proteins," J. Am. Chem. Soc. 97:1427-1439, 1975.
De Venuto et al., "Appraisal of hemoglobin solution as a blood substitute," Surgery Gynecology and Obstetrics 149:417-436, 1979.
Dewhirst et el., "The use of hydralazine to manipulate tumour temperatures during hyperThermia," Int. J. Hyperthermia 6:971-983, 1990.
Feola et al., "Development of a bovine stroma-free hemoglobin solution as a blood substitute," Surgery Gynecology and Obstetrics 157:399-408, 1983.
Froehler, "Synthesis of DNA via deoxynucleotide H-phosphonate intermediates," Nucl. Acids Res. 14:5399-5407, 1986.
Hahn and Shiu, "Protein synthesis, thermotolerance and step down heating," Int. J. Radiat. Oncol. Biol. Phys., 11:159-164, 1985.
Hunkapilar et al., "A microbial facility for the analysis and synthesis of genes and proteins," Nature (London) 310:105-111, 1984.
Jain, "Determinants of tumor blood flow: a review," Cancer Res. 48:2641-2658, 1988.
Jones and Howard, "A rapid method for site-specific mutagenesis and directional subcloning by using the polymerase chain reaction to generate recombinant circles," Biotechniques 8:178-180, 1990.
Kilbourne et al., "N.sup.G -Methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide," Proc. Natl. Acad. Sci. USA 87:3629-3832, 1990.
Labossiere et al., "Hemoglobin Deer Lodge: .alpha..sub.2 .beta..sub.2.sup.2 His.fwdarw.Arg, " Clin. Biochem. 5:46-50, 1972.
Martin et al., "The mechanisms by which haemoglobin inhibits the relaxation of rabbit aorta induced by nitrovasodilators, nitric oxide, or bovine retractor penis inhibitory factor," Br. J. Pharmacol. 89:563-571, 1986.
McCormick and Atorssi, "Hemoglobin binding with haptoglobin: delineation of the haptoglobin binding site on the .alpha.-chain of human hemoglobin," J. Prot. Chem. 9:735, 1990.
Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," J. Chem. Soc. 85:2149-2154, 1963.
Moncada et al., "Nitric oxide: physiology, pathophysiology, and pharmacology," Pharm. Rev. 43:109-142, 1991.
Perutz, "Mechanism of denaturation of haemoglobin by alkali," Nature 247:341, 1974.
Prescott et al., "Use of Nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs," Int. J. Hyperthermia 23:377-385, 1990.
Radomski et al., "Human colorectal adenocarcinoma cells: differential nitric-oxide synthesis determines their ability to aggregate platelets," Cancer Res. 51:6073-6078, 1991.
Robbins and Angell, Basic Pathology, 2dEd., W.B. Saunders Co., Philadelphia, pp. 68-79, 1976.
Sehgal et al., "Polymerized pyrodoxylated hemoglobin: a red cell substitute with normal oxygen capacity," Surgery 95:433-438, 1984.
Sevick and Jain, "Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure," Cancer Res. 49:3506-3512, 1989.
Tentori et al., "Hemoglobin Abruzzo: beta 143 (H21) His.fwdarw.Arg," Clin. Chim. Acta 38:258-262, 1972.
Traylor and Traylor, "Considerations for the design of useful synthetic oxygen carriers," Ann. Rev. Biophys. Bioeng. 11:105-127, 1982.
Winslow et al., "Hemoglobin McKees Rocks (.alpha..sub.2 .beta..sub.2.sup.145 Tyr.fwdarw.Term, " J. Clin. Invest. 57:772-781, 1976.
Wood et al., "Changes in tumour phosphorus metabolism by the nitric oxide donor sin-1," abstract presented at 41st Ann. Meeting of Radiation Research Society, Dallas, Texas, Mar. 20-25, 1993.
Zoller and Smith, "Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single -stranded DNA template," DNA 3:479-488, 1984.
Wilson et al., 1995, Ninth International Conference on Chemical Modifier of Cancer Treatment, abstract NSC 654891, p. 63.
Bonaventura Joseph
DeAngelo Joseph
Dewhirst Mark W.
Meyer Robert E.
Apex Bioscience, Inc.
Duke University
North Carolina State University
Peabody John
Richter Johann
LandOfFree
Methods for improving therapeutic effectiveness of agents for th does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for improving therapeutic effectiveness of agents for th, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for improving therapeutic effectiveness of agents for th will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1706359